ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/02/2025
Back to search
Official data from USPTO
APGAVI
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
04/03/2025
Trademark type
Word
Nice classes
5
Filing date
09/08/2020
Registration date
03/14/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/14/2023
Last transaction
04/03/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
03
Owner location
Suzhou, Jiangsu, CN
Examiner
FAUCETTE,MAX C
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
ASCENTAGE PHARMA (SUZHOU) CO., LTD.
ASCENTAGE PHARMA (SUZHOU) CO., LTD.
ASCENTAGE PHARMA GROUP CORP LIMITED
Representatives
Kathryn E. Smith Wood Herron & Evans LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for dental purposes; Chemical preparations for medical purposes for treating cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Antibiotics; Injectable medicines for treating cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Medicine in tablet form for treating cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Drugs sold in bulk for treating cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Biochemical medicines for use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Antiseptics; Collyrium; Hemorrhoidal suppositorieslaxative suppositoriesvaginal suppositories for the prevention and treatment of infections; Medical pastermedical plasters; Diagnostic preparations for medical purposes; Diagnostic biomarker reagents for medical purposes; Medicated sweets; Candy for medical purposes; Dietetic foods adapted for medical purposes; Dietetic beverages adapted for medical purposes; Dietetic preparations adapted for medical purposes; Medicinal oils; Mineral food supplements; Nutritional supplements; Medicines for human purposes for use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Bacterial poisons; Pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Chemico-pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Drugs for medical purposes in the nature of prescription apoptosis targeted compoundsnext-generation kinase inhibitors and senolytic drugs; Biological preparations for medical purposesbiological preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Chemical preparations for pharmaceutical purposesfor use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; Radioactive substances for medical purposes; Gases for medical purposesnitric oxide for medical purposes; Chemical conductors for electrocardiograph electrodes; Semen for artificial insemination; Disinfectants; Solutions for contact lenses; Media for bacteriological cultures; Depuratives for the body; Diagnostic preparations for veterinary purposes; Pesticides; Sanitary napkins; Cotton for medical purposes; Dental abrasives; Diapers for pets
Publications
History of USPTO decisions and trademark events.
33 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/14/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
03/14/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/27/2022
PUBO
PUBLISHED FOR OPPOSITION
12/27/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/07/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/21/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/21/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/20/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/20/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/09/2022
GNRT
NON-FINAL ACTION E-MAILED
06/09/2022
CNRT
NON-FINAL ACTION WRITTEN
06/09/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/18/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/18/2022
ALIE
ASSIGNED TO LIE
05/17/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
05/12/2022
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/17/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/17/2021
CNSI
SUSPENSION INQUIRY WRITTEN
11/17/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
10/27/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/21/2021
GNSL
LETTER OF SUSPENSION E-MAILED
04/21/2021
CNSL
SUSPENSION LETTER WRITTEN
04/21/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/31/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/30/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/30/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/06/2021
GNRT
NON-FINAL ACTION E-MAILED
01/06/2021
CNRT
NON-FINAL ACTION WRITTEN
01/06/2021
DOCK
ASSIGNED TO EXAMINER
01/05/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/13/2020
NWAP
NEW APPLICATION ENTERED
09/11/2020
Continuous trademark protection
Get notified about every new filing that threatens APGAVI or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.